|
Video: What is a Stock Split?
|
|
23andMe Holding is engaged in developing direct-to-consumer precision medicine platform and a portfolio of genetically validated therapeutic candidates for various diseases across different therapeutic areas. Co.'s segments are: Consumer and Research Services, which provides its Personal Genome Service® telehealth business and research services; and Therapeutics, which focuses on the use of genetic insights from its database of genetic and phenotypic information to develop therapies and consists of out-licensing of intellectual property associated with identified drug targets and activities related to therapeutic product candidates. According to our 23andMe Holding stock split history records, 23andMe Holding has had 0 splits. | |
|
23andMe Holding (ME) has 0 splits in our 23andMe Holding stock split history database.
Looking at the 23andMe Holding stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into 23andMe Holding shares, starting with a $10,000 purchase of ME, presented on a split-history-adjusted basis factoring in the complete 23andMe Holding stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
01/05/2021 |
|
End date: |
04/24/2024 |
|
Start price/share: |
$11.40 |
|
End price/share: |
$0.47 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-95.90% |
|
Average Annual Total Return: |
-62.04% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$409.59 |
|
Years: |
3.30 |
|
|
|
|
|